semaglutide and dialysis Kidney care is entering a whole new era 💙 With the 2025 FDA approval of Ozempic (semaglutide) to help slow chronic kidney disease in people with type 2 diabetes, patients now have Effects of Once-Weekly Semaglutide on

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

Patients using semaglutide typically lose 12 pounds weekly, though results vary based on starting weight, lifestyle, and genetic factors

By activating the GLP1 receptor, it reduces your appetite, slows how quickly your stomach empties, and helps you feel full sooner and for longer

Maximize your FSA benefits and lose weight at the same time

Heard the whispers, haven't you

As patents of Semaglutide begin to expire globally, dozens of pharmaceutical companies are preparing to enter a market currently dominated by Novo Nordisk through blockbuster brands like Ozempic and Wegovy